AtriCure Resultados de beneficios anteriores

Pasado controles de criterios 0/6

AtriCure ha aumentado sus beneficios a una tasa media anual de 7.1%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento anual de 13.5%. Los ingresos han ido creciendo a una tasa media de 14.3% al año.

Información clave

4.8%

Tasa de crecimiento de los beneficios

8.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	15.1%
Rentabilidad financiera	-8.2%
Margen neto	-9.0%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20

Desglose de ingresos y gastos

Cómo gana y gasta dinero AtriCure. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:ATRC Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	415	-37	270	78
31 Dec 23	399	-30	258	74
30 Sep 23	381	-25	241	67
30 Jun 23	366	-28	241	62
31 Mar 23	349	-38	235	59
31 Dec 22	330	-46	231	57
30 Sep 22	316	-56	229	57
30 Jun 22	303	53	221	54
31 Mar 22	290	52	214	51
31 Dec 21	274	50	205	49
30 Sep 21	259	45	190	46
30 Jun 21	243	-57	174	45
31 Mar 21	213	-49	151	43
31 Dec 20	207	-48	151	43
30 Sep 20	210	-46	147	45
30 Jun 20	212	-50	157	45
31 Mar 20	230	-46	165	45
31 Dec 19	231	-35	167	41
30 Sep 19	222	-23	159	37
30 Jun 19	216	-20	150	35
31 Mar 19	209	-17	144	34
31 Dec 18	202	-21	140	35
30 Sep 18	195	-20	135	34
30 Jun 18	187	-20	130	33
31 Mar 18	180	-27	126	34
31 Dec 17	175	-27	121	34
30 Sep 17	170	-33	116	36
30 Jun 17	166	-32	111	37
31 Mar 17	160	-34	109	37
31 Dec 16	155	-33	105	36
30 Sep 16	150	-36	106	34
30 Jun 16	143	-35	102	32
31 Mar 16	135	-32	97	29
31 Dec 15	129	-27	91	26
30 Sep 15	123	-22	85	23
30 Jun 15	118	-16	83	22
31 Mar 15	112	-14	78	20
31 Dec 14	107	-16	78	19
30 Sep 14	99	-16	74	17
30 Jun 14	93	-18	68	15
31 Mar 14	87	-17	65	14
31 Dec 13	81	-11	57	13
30 Sep 13	78	-9	50	13
30 Jun 13	74	-8	47	12

Ingresos de calidad: ATRC actualmente no es rentable.

Margen de beneficios creciente: ATRC actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ATRC no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 7.1% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ATRC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ATRC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (7.5%).

Rentabilidad financiera

Alta ROE: ATRC tiene una rentabilidad financiera negativa (-6.53%), ya que actualmente no es rentable.

AtriCure Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Insider notifies of intention to sell stock

Price target decreased to US$69.50

AtriCure, Inc. to Report Q2, 2022 Results on Aug 02, 2022